Collaboration Agreements And Business Development Activities -Royalty Pharma Narrative (Details) - USD ($) $ in Millions |
3 Months Ended | |
|---|---|---|
Mar. 29, 2024 |
Mar. 31, 2023 |
|
| Collaborative Arrangements with Glaxo Smith Kline | ||
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||
| Percent of royalty on net sale | 3.00% | |
| Collaborative Arrangements with Royalty Pharma | ||
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||
| Royalty expense | $ 16.7 | $ 15.4 |